Yes. For example, last year we followed a process on the Cox-2 inhibitors, namely Vioxx, Celebrex and other such drugs. A group of experts was created to investigate the matter. Up to then, it was customary to have experts discuss matters among themselves and then make recommendations to the department. We opted for a model that already exists in the United States, in the Food and Drug Administration. The public was invited to voice its opinions.
Even if such opinions are not strictly scientific, we thought that it was important to gather the comments of people who have used these drugs. Therefore, we tried to be more open and to consult the public.